Description     Claims     Drawing  

US5736368A   [0001] 
US6051410A   [0001] 
US5747324A   [0001]  [0001] 
EP0243029A   [0001] 
WO2010102822A   [0004]  [0118] 
US5766A   [0037]  [0039]  [0040] 
US598A   [0037]  [0039]  [0040] 
US5833975A   [0037] 
WO0242480A   [0052]  [0055]  [0056]  [0057]  [0058]  [0059] 
US6761893B   [0055]  [0055] 
WO03097844A   [0107] 

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus   [0001] 
Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus   [0001] 
High-level expression of Amsacta moorei entomopoxvirus spheroidin depends on sequences within the gene   [0001] 
Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara   [0002] 
Structure of Vaccinia Virus Late Promoters   [0004] 
Structure of Vaccinia Virus Early Promoters   [0004] 
Mutational Analysis of a Vaccinia Virus Intermediate Promoter in vitro and in vivo   [0004] 
Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing   [0004] 
Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes   [0004] 
Structure of vaccinia virus early promoters   [0004] 
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine   [0006] 
Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response   [0006] 
Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination.   [0007]  [0008] 
Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines   [0008]  [0009] 
Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses   [0009]  [0009] 
Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression   [0010]  [0010] 
Journal of Virology   [0011]  [0021] 
Clinical and Vaccine Immunology   [0012] 
Virulence   [0012] 
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species   [0037]  [0037] 
The basis for HIV immunotherapeutic vaccines   [0037] 
A new mutant of dermovaccinia virus   [0042] 
Structural analysis of vaccinia virus Dls strain: Application as a new replication-deficient viral vector   [0042] 
NYVAC: A highly attenuated strain of vaccinia virus   [0043] 
Passage History: Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA   [0046] 
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence   [0046] 
Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara   [0046] 
Vaccination against pox diseases under immunosuppressive conditions   [0046] 
Zbl. Bakt. Hyg. I   [0047] 
MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)   [0047] 
Smallpox vaccination and its consequences: first experiences with the highly attenuated smallpox vaccine ''MVA   [0047] 
Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (''MVA virus)   [0047] 
The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism (author's transl)   [0047] 
Highly attenuated modified vaccinia Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells   [0057] 
Nonreplicating vaccinia vector efficiently expresses recombinant genes   [0061] 
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line   [0061] 
Therapeutic Vaccination of HIV-1-infected patients on HAART with recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption   [0061] 
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals   [0061] 
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial   [0061] 
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma   [0061] 
Compact, Synthetic, Vaccinia Virus Early Late Promoter for Protein Expression   [0067] 
Structure of vaccinia virus early promoters   [0069] 
Nucl. Acids Res.   [0076] 
Nucl. Acids Res.   [0076] 
Atlas of Protein Sequence and Structure   [0076] 
J. Mol. Biol.   [0077] 
J. Mol. Biol.   [0077] 
Vaccinia virus transcription   [0107] 
Compact, synthetic, vaccinia virus early/late promoter for protein expression   [0107] 
J. Mol. Biol.   [0107]